Seminars in Oncology
Volume 33, Issue 5 , Pages 576-582 , October 2006

Adjuvant Therapy for Renal Cell Carcinoma

  • Kenneth M. Jacobsohn

      Affiliations

    • The University of Texas Health Science Center-Houston, Houston, TX.
    • ,
  • Christopher G. Wood

      Affiliations

    • The University of Texas M.D. Anderson Cancer, Houston, TX.
    • Corresponding Author InformationAddress correspondence to Christopher G. Wood, MD, FACS, Associate Professor of Urology, Department of Urology–Unit 1373, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  2. In:  Ries LAG,  Eisner MP,  Kosary CL, et al. editor. SEER Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute; 2004;http://seer.cancer.gov/csr/1975_2001
  3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865–875
  4. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170:2163–2172
  5. Rabinovitch R, Zelefsky MJ, Gaynor JJ, et al. Patterns of failure following surgical resection of renal cell carcinoma: Implications for adjuvant local and systemic therapy. J Clin Oncol. 1994;12:206–212
  6. Levy DA, Slaton JW, Swanson DA, et al. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 1998;159:1163–1167
  7. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649–1657
  8. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J Urol. 2002;168:2395–2400
  9. Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63–67
  10. Cindolo L, de la Taille A, Messina G, et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int. 2003;92:901–905
  11. Yaycioglu O, Roberts WW, Chan T, et al. Prognostic assessment of nonmetastatic renal cell carcinoma: A clinically based model. Urology. 2001;58:141–145
  12. Finney R. The value of radiotherapy in the treatment of hypernephroma—A clinical trial. Br J Urol. 1973;45:258–269
  13. Kjaer M, Iversen P, Hvidt V, et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. Scand J Urol Nephrol. 1997;21:285–289
  14. Aref I, Bociek RG, Salhani D. Is post-operative radiation for renal cell carcinoma justified?. Radiother Oncol. 1997;43:155–157
  15. Pizzocaro G, Piva L, Di Fronzo G. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol. 1987;138:1379–1381
  16. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol. 1995;22:42–60
  17. Asakura T, Imai A, Ohkubo-Uraoka N, et al. Relationship between expression of drug-resistance factors and drug sensitivity in normal human renal proximal tubular epithelial cells in comparison with renal cell carcinoma. Oncol Rep. 2005;14:601–607
  18. Masuda F, Nakada J, Kondo I, et al. Adjuvant chemotherapy with vinblastine Adriamycin and UFT for renal-cell carcinoma. Cancer Chemother Pharmacol. 1992;30:477–479
  19. Rosenberg A. Principles of management: Biological therapy. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer Principles and Practice of Oncology. (ed 5).. Philadelphia, PA: Lippincott-Raven; 1997;p. 349–373
  20. Sanchez-Ortiz RF, Tannir N, Ahrar K, et al. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: An in situ tumor vaccine?. J Urol. 2003;170:178–179
  21. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: A case with 5-year followup. J Urol. 1992;148:1247–1248
  22. Bleumer I, Oosterwijk E, De Mulder P, et al. Immunotherapy for renal cell carcinoma. Eur Urol. 2003;44:65–75
  23. Vuky J, Motzer RJ. Cytokine therapy in renal cell cancer. Urol Oncol. 2000;5:249–257
  24. Basting R, Corvin S, Handel D, et al. Adjuvant immunotherapy in renal cell carcinoma—Comparison of interferon alpha treatment with an untreated control. Anticancer Res. 1999;19:1545–1548
  25. Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: A multicentric randomized study. J Clin Oncol. 2001;19:425–431
  26. Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 2003;21:1214–1222
  27. Jeon SH, Chang SG, Kim JI. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma. Anticancer Res. 1999;19:5593–5597
  28. Migliari R, Muscas G, Solinas A, et al. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma?. J Chemother. 1995;7:240–245
  29. van Spronsen DJ, Mulders PF, De Mulder PH. Novel treatments for metastatic renal cell carcinoma. Crit Rev Oncol Hemat. 2005;55:177–191
  30. Fyfe G, Fisher SA, Sznol M, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688–696
  31. Fisher RI, Rosenberg SA, Sznol M, et al. High-dose aldesleukin in renal cell carcinoma: Long-term survival update. Cancer J Sci Am. 1997;3(suppl 1):S70–S72
  32. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A Cytokine Working Group randomized trial. J Clin Oncol. 2003;21:3133–3140
  33. Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: Five-year results of a prospective randomized study. Cancer. 1996;77:2560-2506
  34. Repmann R, Goldschmidt AJ, Richter A. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: A 5-year follow-up analysis. Anticancer Res. 2003;23:969–974
  35. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomized controlled trial. Lancet. 2004;363:594–599
  36. Srivastava PK. Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr Oncol Rep. 2005;7:104–108
  37. Assiki VJ, Daliani D, Pagliaro L, et al. Phase II study of autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2003;22:386;(abstr)
  38. Cheson BD. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. Biodrugs. 2005;19:309–322
  39. Bleumer I, Knuth A, Oosterwijk E, et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer. 2004;90:985–990
  40. Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 1995;55:4182–4187
  41. Sistla A, Sunga A, Phung K, et al. Powder-in-bottle formulation of SU011248 (Enabling rapid progression into human clinical trials). Drug Dev Ind Pharm. 2004;30:19–25
  42. Bollag G, Freeman S, Lyons JF, et al. Raf pathway inhibitors in oncology. Curr Opin Investig Drugs. 2003;4:1436–1441
  43. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer. 2005;92:1855–1861
  44. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res. 2004;10:6388–6392
  45. Ratain MJ, Flaherty KT, Stadler WM, et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT), ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol. 2004;22(suppl 14S):4500
  46. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. J Clin Oncol. 2005;23(16S):(suppl, abstr 4510)
  47. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16–24
  48. Motzer RJ, Rini BI, Michaelson MD, et al. The SU11248 study group, phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). J Clin Oncol. 2005;23(16S):(suppl, abstr 4508)
  49. Amato RJ. Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol. 2003;46:S59–S65
  50. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–1571
  51. Eisen T, Boshoff C, Mak I, et al. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer. 2000;82:812–817
  52. Sninivas S, Guardino AF. Randomized phase II trial of high and low dose thalidomide in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2002;21:147b;(abstr)
  53. Li Z, Amato R, Papandreou C, et al. Phase II study of thalidomide for patients with metastatic renal cell carcinoma (MRCC) progressing after interleukin-2 (IL-2)-based therapy. Proc Am Soc Clin Oncol. 2001;20:180a;(abstr)
  54. Motzer RJ, Berg W, Ginsburg M, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol. 2002;20:302–306
  55. Novik Y, Dutcher JP, Larkin M, et al. Phase II study of thalidomide (T) in advanced refractory metastatic renal cell cancer (MRCC); a single institution experience. Proc Am Soc Clin Oncol. 2001;20:265a;(abstr)

PII: S0093-7754(06)00271-5

doi: 10.1053/j.seminoncol.2006.06.005

Seminars in Oncology
Volume 33, Issue 5 , Pages 576-582 , October 2006

Article Tools